# Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement

> **NCT00869206** · PHASE3 · COMPLETED · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 1822 (actual)

## Conditions studied

- Breast Adenocarcinoma
- DS Stage I Plasma Cell Myeloma
- DS Stage II Plasma Cell Myeloma
- Metastatic Malignant Neoplasm to the Bone
- Pain
- Musculoskeletal Complication
- Urinary Complications

## Interventions

- **DRUG:** zoledronic acid

## Key facts

- **NCT ID:** NCT00869206
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2014-06
- **Final completion:** 2017-01
- **Target enrollment:** 1822 (ACTUAL)
- **Last updated:** 2018-11-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00869206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00869206, "Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00869206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*